Literature DB >> 18549309

Identification and allele-specific silencing of the mutant huntingtin allele in Huntington's disease patient-derived fibroblasts.

P H J van Bilsen1, L Jaspers, M S Lombardi, J C E Odekerken, E N Burright, W F Kaemmerer.   

Abstract

Huntington's disease (HD) is a dominantly inherited neurodegenerative disorder caused by the expression of mutant huntingtin protein (Htt). Suppression of Htt expression, using RNA interference, might be an effective therapy. However, if reduction of wild-type protein is not well tolerated in the brain, it may be necessary to suppress just the product of the mutant allele. We present a small interfering RNA (siRNA) that selectively reduces the endogenous mRNA for a heterozygous HD donor's pathogenic allele by approximately 80% by specifically targeting a single-nucleotide polymorphism (SNP) located several thousand bases downstream from the disease-causing mutation. In addition, we show selective suppression of endogenous mutant Htt protein, using this siRNA. We further present a method, using just a heterozygous patient's own mRNA, to determine which SNP variants correspond to the mutant allele. The method may be useful in any disorder in which a targeted SNP is far downstream from the pathogenic mutation. These results indicate that allele-specific treatment for Huntington's disease may be clinically feasible and practical.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18549309     DOI: 10.1089/hum.2007.116

Source DB:  PubMed          Journal:  Hum Gene Ther        ISSN: 1043-0342            Impact factor:   5.695


  56 in total

Review 1.  Experimental surgical therapies for Huntington's disease.

Authors:  Jelle Demeestere; Wim Vandenberghe
Journal:  CNS Neurosci Ther       Date:  2010-12-28       Impact factor: 5.243

2.  Moving toward a gene therapy for Huntington's disease.

Authors:  J C Glorioso; J B Cohen; D L Carlisle; I Munoz-Sanjuan; R M Friedlander
Journal:  Gene Ther       Date:  2015-12       Impact factor: 5.250

Review 3.  Allele-selective inhibition of trinucleotide repeat genes.

Authors:  Masayuki Matsui; David R Corey
Journal:  Drug Discov Today       Date:  2012-01-18       Impact factor: 7.851

Review 4.  Oligonucleotide therapeutic approaches for Huntington disease.

Authors:  Dinah W Y Sah; Neil Aronin
Journal:  J Clin Invest       Date:  2011-02-01       Impact factor: 14.808

5.  Allele-selective inhibition of huntingtin expression by switching to an miRNA-like RNAi mechanism.

Authors:  Jiaxin Hu; Jing Liu; David R Corey
Journal:  Chem Biol       Date:  2010-11-24

6.  Tailor-made RNAi knockdown against triplet repeat disease-causing alleles.

Authors:  Masaki Takahashi; Shoko Watanabe; Miho Murata; Hirokazu Furuya; Ichiro Kanazawa; Keiji Wada; Hirohiko Hohjoh
Journal:  Proc Natl Acad Sci U S A       Date:  2010-11-22       Impact factor: 11.205

7.  Expanded CAG repeats in the crosshairs.

Authors:  Neil Aronin
Journal:  Nat Biotechnol       Date:  2009-05       Impact factor: 54.908

Review 8.  Lentiviral vector-mediated RNA silencing in the central nervous system.

Authors:  Thomas H Hutson; Edmund Foster; Lawrence D F Moon; Rafael J Yáñez-Muñoz
Journal:  Hum Gene Ther Methods       Date:  2013-11-01       Impact factor: 2.396

9.  Data analysis issues for allele-specific expression using Illumina's GoldenGate assay.

Authors:  Matthew E Ritchie; Matthew S Forrest; Antigone S Dimas; Caroline Daelemans; Emmanouil T Dermitzakis; Panagiotis Deloukas; Simon Tavaré
Journal:  BMC Bioinformatics       Date:  2010-05-26       Impact factor: 3.169

10.  Allele-specific silencing of mutant huntingtin and ataxin-3 genes by targeting expanded CAG repeats in mRNAs.

Authors:  Jiaxin Hu; Masayuki Matsui; Keith T Gagnon; Jacob C Schwartz; Sylvie Gabillet; Khalil Arar; Jun Wu; Ilya Bezprozvanny; David R Corey
Journal:  Nat Biotechnol       Date:  2009-05-03       Impact factor: 54.908

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.